Raloxifene Hydrochloride CAS 82640-04-8 For Breast Cancer Osteoporosis

Raloxifene Hydrochloride powder CAS 82640-04-8 Raloxifene HCL for Anti Estrogen

Description:

Raloxifen hydrochloride, a second-generation Selective Estrogen Receptor Modulator (SERM) in

the Raloxifene hydrochloride benzothiophene family. On September 13, 2007, the U. S. Food and

Drug Administration approved Evista for reduction in the risk of invasive breast cancer in

postmenopausal women with and Raloxifene hydrochloride without osteoporosis. It has also been

approved as a potent stand-alone osteoporosis treatment.


Application:

Raloxifene hydrochlorideMay prevent or treat corticosteroid-induced bone loss .American

College of Rheumatology states that raloxifene can be offered to selected postmenopausal

corticosteroid-treated women who refuse hormone replacement therapy or other Raloxifene

hydrochloride antiresorptive agents or in whom such therapies are contraindicated.

Reduction in the incidence Raloxifene hydrochloride of invasive breast cancer in postmenopausal

women with osteoporosis.

Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for

developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive

breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma

in situ (STAR trial). Effect on breast cancer incidence in women with Raloxifene hydrochloride

BRCA1 or BRCA2 genetic mutations not established.

Related products:

Contact US